News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Up To $330M CAD ($324 Million USD) International Partnership Between Bayer HealthCare Pharmaceuticals (BAYA.F) And EndoCeutics


10/5/2010 10:50:15 AM

QUÉBEC, Oct 5 /CNW Telbec/ - Bayer HealthCare Pharmaceuticals (Bayer) and EndoCeutics Inc., Québec, are proud to announce the signing of an exclusive international collaborative agreement for Phase III development and marketing of Dehydroepiandrosterone (DHEA), a new treatment for vaginal atrophy and female sexual dysfunction.

Read at Canada NewsWire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES